March 2023 FDA Recall Brimonidine Tartrate by Apotex Corp.
D-0433-2023 - Lack of sterility assurance

This Class II drug recall was voluntarily initiated by Apotex Corp. on March 1, 2023 for the product Brimonidine Tartrate. The FDA reported the reason for recall as lack of sterility assurance. The product was distributed Nationwide and the recall is currently completed.

Recall Number: D-0433-2023

Reason for Recall
Lack of sterility assurance: Cracks have developed in some of the units caps of Brimonidine tartrate ophthalmic solution bottles. There is a possibility the broken cap may impact sterility.
Initiated
03-01-2023
Reported
03-15-2023
Quantity
67,056 bottles

Recall Profile & Regulatory Data

Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Nationwide in the USA
Brimonidine Tartrate Ophthalmic Solution 0.15%, Rx Only, Packaged as: a) 5 mL dropper bottle, NDC 60505-0564-1, UPC 3 60505 05641 5; b) 10 mL dropper bottle NDC 60505-0564-2, UPC 3 60505 05642 2; c) 15 mL dropper bottle, NDC 60505-0564-3, UPC 3 60505 05643 9; Manufactured by: Apotex Inc. Toronto, Ontario Canada M9L 1T9 Manufactured for: Apotex Corp. Weston, FL 33326

Batch or Lot Expiration Information

Lot# Lots: a) TJ9848 Exp. 02/2024, TJ9849 Exp. 02/2024, TK0258 Exp. 04/2024, TK5341 Exp. 04/2024; b) TK0261 Exp. 04/2024; c) TK0262 Exp. 04/2024